CHT [CHUNGHWA TELECOM CO] 6-K: (Original Filing)
[Description 99.01 Announcement on 2020/04/17: To announce the differences between the year of 2019 financial statements under Taiwan-IFRSs and IFRSs 2 Chunghwa Telecom Co., Ltd. Shui-Yi Kuo]
[Description 99.01 Announcement on 2020/04/17: To announce the differences between the year of 2019 financial statements under Taiwan-IFRSs and IFRSs 2 Chunghwa Telecom Co., Ltd. Shui-Yi Kuo]
[Description 99.01 Announcement on 2020/04/17: To announce the differences between the year of 2019 financial statements under Taiwan-IFRSs and IFRSs 2 Chunghwa Telecom Co., Ltd. Shui-Yi Kuo]
[( a j o i n t s t ock li m i t ed co m pa ny i n co r p o r a t ed i n t h e P e o p l e s R e p ub l i c o f C h i na) (Stock Code: 00525) PROFIT WARNING] [Number Description of Document 99.1 Profit Warning Regarding Preliminary First Quarter 2020 Results 6-K 20-F Certain information contained in]
[( a j o i n t s t ock li m i t ed co m pa ny i n co r p o r a t ed i n t h e P e o p l e s R e p ub l i c o f C h i na) (Stock Code: 00525) PROFIT WARNING] [Number Description of Document 99.1 Profit Warning Regarding Preliminary First Quarter 2020 Results 6-K 20-F Certain information contained in]
[This statement is filed in connection with (check the appropriate box): a. ☐ 13e-3(c) The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule]
[Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING --(BUSINESS WIRE)-- April 17, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Compa]